Valiant Laboratories Limited (NSE:VALIANTLAB)
India · Delayed Price · Currency is INR 77.25
+1.28 (1.68%)
May 22, 2026, 3:25 PM IST
Valiant Laboratories Revenue
In the fiscal year ending March 31, 2026, Valiant Laboratories had annual revenue of 2.40B INR with 79.78% growth. Valiant Laboratories had revenue of 921.53M in the quarter ending March 31, 2026, with 59.47% growth.
Revenue
2.40B
Revenue Growth
+79.78%
P/S Ratio
1.76
Revenue / Employee
30.06M
Employees
79
Market Cap
4.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.40B | 1.06B | 79.78% |
| Mar 31, 2025 | 1.33B | -486.75M | -26.74% |
| Mar 31, 2024 | 1.82B | -1.52B | -45.48% |
| Mar 31, 2023 | 3.34B | 215.43M | 6.90% |
| Mar 31, 2022 | 3.12B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nectar Lifesciences | 16.70B |
| Windlas Biotech | 9.22B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.96B |
| Jagsonpal Pharmaceuticals | 2.87B |
| Balaxi Pharmaceuticals | 2.76B |
| Bafna Pharmaceuticals | 1.47B |